We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Based Prenatal Blood Test Identifies Dangerous Fetal Heart Defects before Birth

By LabMedica International staff writers
Posted on 19 Oct 2022

Birth defects, particularly ones that stem from heart disease, are a leading cause of infant mortality. More...

These include a hole in the heart, the most common, and other potentially deadly cardiac birth defect that might affect oxygen levels and blood flow at birth; valve and other abnormalities. Currently, ultrasound which images the fetal heart, is the only available screening tool for early (prenatal) detection of congenital heart defects. Unfortunately, in the U.S., only about half of fetal congenital heart defects are identified on prenatal ultrasound. Because of this limitation, it is now the standard of care to screen and monitor newborn oxygen levels, via pulse oximetry. However, pulse oximetry still misses about 10% of critical newborn heart defects, leading to increased deaths and severe complications. Now, a new blood test for pregnant women uses artificial intelligence (AI) and genetic-related biomarkers to accurately detect, fetal congenital heart defects, well before birth.

Smoking, alcohol use, environmental toxins and vitamin deficiency are all known contributors to the development of congenital heart defects. These agents cause chemical (‘epigenetic’) changes in DNA which can affect the function of genes critical to the development of the heart by turning genes on or off. Researchers at Beaumont Hospital (Southfield, MI, USA) along with colleagues from three other institutions harnessed the power of AI to identify and evaluate fetal DNA that circulates in the mother’s bloodstream. AI analysis of the circulating (including fetal) DNA extracted from the mother’s blood enabled the researchers to efficiently review potentially billions of pieces of information in the genome. This included swiftly identifying specific predictors of a possible fetal heart defect and separating those that need continued monitoring.

The researchers caution that larger, prospective studies are needed to validate these findings. However, this minimally invasive detection method is an important, first step in establishing an effective, postnatal action plan that quickly puts at-risk infants on track to receive the intensive medical and surgical attention they need. Ultimately, the researchers would like to see all pregnant women achieve ready access to screening- through a blood test, which requires no advance appointments or significant time off from work. Those who test positive could then be referred for detailed, fetal, and newborn cardiac ultrasounds and appropriate early intervention, as needed.

“Once confirmed, these results could lead to exciting new protocols and, most importantly, improved outcomes for newborns and their families,” said Dr. Ray Bahado-Singh, system chief of Obstetrics and Gynecology, Beaumont Health, and lead author of the study. “The next steps after a positive test would include performing an echocardiogram prenatally and repeated after birth to confirm the presence and nature of a cardiac defect.”

Related Links:
Beaumont Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Clinical Chemistry Analyzer
Envoy 500+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.